Company Overview
Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
Aug 17 2020, 7:00 AM EDT

Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
Aug 10 2020, 4:01 PM EDT

Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
Jul 10 2020, 7:30 AM EDT

Management Team
João Siffert, M.D.
Chief Executive Officer, Head of Research & Development and Chief Medical Officer

Michael Amoroso
Senior Vice President and Chief Commercial Officer

Jay Bircher
Chief Technical Officer

Edward Carr
Chief Accounting Officer, Principal Financial Officer

Victor Paulus, Ph.D.
Senior Vice President, Head of Regulatory Affairs

Juan Ruiz, M.D., Ph.D.
Head of European Medical Affairs

Jodie Gillon, M.P.H.
Vice President, Patient Advocacy & Clinical Affairs

Brendan O'Malley, J.D., Ph.D.
Vice President, Head of Legal and IP

Kristina Maximenko
Vice President, Human Resources

Scott Nogi
Vice President, Business Operations

Abeona Therapeutics Inc.
1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.